Table 1. Characteristics of studies included in the meta-analysis.
| Study | Year | Country | Study design | Cases | Cycles of TMZ | Mean age, (years) | KPS at diagnosis | M/F | Histology | RT | Median PFS (months) | Median OS (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seiz | 2010 | Germany | R | 114 | 6C (55) | 62 | na | 74/40 | IV (55) | 114 | 7 | 15 |
| Long-term (59) | na | IV (59) | ||||||||||
| Freyschlag | 2011 | Germany | R | 42 | 6C (11) | 38.5 | na | 25/17 | III (11) | 42 | 22.2 | 39 |
| Long-term (31) | III (31) | |||||||||||
| Gloria B. | 2012 | Canada | R | 52 | 6C (23) | 53 | 90 | 13/10 | IV (23) | 23 | 11.8 | 16.5 |
| Long-term (29) | 55 | 80 | 19/10 | IV (29) | 29 | 15.6 | 24.6 | |||||
| Darlix | 2013 | France | R | 58 | 6C (38) | 56.3 | 80 | 28/10 | IV (38) | 38 | 18 | 28.2 |
| Long-term (20) | 52.6 | 76.7 | 10/10 | IV (20) | 20 | 28.4 | 30 | |||||
| Barbagallo | 2014 | Italy | R | 37 | 6C (18) | 64.8 | 62.2 | 9/9 | IV (18) | 18 | 4 | 8 |
| Long-term (19) | 56.1 | 71.5 | 10/9 | IV (19) | 19 | 20 | 28 | |||||
| Weilin | 2016 | China | R | 93 | 6C (48) | 50 | 86.7 | 29/19 | III (23);IV (25) | 45 | 21 | 28 |
| Long-term (45) | 43 | 85.4 | 34/11 | III (16);IV (29) | 48 | 29 | 39 |
R: respective; P: prospective; M: male; F: female; TMZ: temozolomide; 6C: 6 cycles of temozolomide. KPS: Karnofsky performance status; RT: radiotherapy; PFS: progress free survival; OS: overall survival.